Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03397394 · ClinicalTrials.gov registry record · Phase 2
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 2 study, sponsored by pharmaand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT03397394 is a Phase 2 study that was terminated before completion, run by pharmaand. The registered enrollment target is 97 participants.
The verdict
NCT03397394, a Phase 2 study, was terminated before completion, sponsored by pharmaand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03397394
The ClinicalTrials.gov registry entry for NCT03397394 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT03397394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03397394 about?
NCT03397394 is a clinical study titled "Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma". The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
What is the current status of trial NCT03397394?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2018-06-01. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT03397394?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03397394?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.